Clinical trials: Contraception
- Condition Contraception
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Contraception
Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear.
- Trial name
- NCT00196326
- Testing
- DR-1011
- Where
- 55 sites in United States
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Contraception
The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol
This study will evaluate the effect of Annovera and tampon co-usage on the pharmacokinetics (PK) of segesterone acetate (SA) and ethinyl estradiol (EE).
- Trial name
- NCT04272008
- Testing
- Segesterone Acetate and Ethinyl Estradiol, Tampon
- Where
- 2 sites in United States, Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- TherapeuticsMD
Contraception
Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
A single-center, randomized, open-label, parallel-group, multi-arm, phase II clinical trial in healthy women aged 18 to 35 years who have a documented ovulatory cycle prior to randomization.
- Trial name
- NCT06048536
- Testing
- MR-130A-01 Transdermal patch
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Contraception
FemBloc® Permanent Contraception - Early Pivotal Trial
Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control).
- Trial name
- BLOC (NCT03433911)
- Testing
- FemBloc, Laparoscopic bilateral tubal sterilization
- Where
- 12 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Femasys Inc.
Contraception
Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study
This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel…
- Trial name
- NCT00528112
- Testing
- LCS12, LCS16
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 2,885 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2
This is an open-label, multi-centre, comparative study in young, healthy, female volunteers of reproductive age. Primary objective: To investigate the effect of 2 dosages of estetrol combined with P1 or P2, on vaginal bleeding…
- Trial name
- FIESTA (NCT01221831)
- Where
- 10 sites in Finland
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Estetra
Contraception
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol.
- Trial name
- NCT01699022
- Testing
- Injection Cyclofem
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Contraception
A Multicentre, Prospective, Open-label, Non-comparative Study
As there are no recent studies conducted in Italy on the profile of this COC, the purpose of this study is to evaluate its efficacy and tolerability in a given subset of women residing in Italy that are in need of contraception.
- Trial name
- NCT06067256
- Testing
- Female Contraceptive
- Where
- Italy
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Contraception
FR01 and FR20 IUS (Intrauterine System) Wearing Study
The aim of the study is to evaluate two different placebo intrauterine systems, placebo FR01 and FR20 with different types of inserters, for wearing comfort, insertion/removal ease and pain compared to a placebo T-frame…
- Trial name
- NCT01595022
- Where
- 10 sites in Finland, Netherlands and 1 more
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.
Contraception, Women at Risk for Pregnancy
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept
- Trial name
- NCT04457076
- Testing
- LevoCept
- Where
- 27 sites in United States
- Volunteers
- 1,525 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
To evaluate the safety and long-term (approximately one year) effectiveness of the Essure System for Permanent Birth Control ESS505 device in preventing pregnancy.
- Trial name
- NCT01861886
- Testing
- ESS505 (BAY1454033)
- Where
- 5 sites in Netherlands, Spain
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study
The present study is designed to determine the effect of valproic acid (VAL), a UGT2B7 inhibiting drug, on the pharmacokinetics (PK) of estetrol (E4)
- Trial name
- NCT03512860
- Testing
- E4/DRSP, VAL
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Estetra
Contraception
Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)
This study will collect information on cycle control, acceptability and tolerability of the vaginal contraceptive ring (NuvaRing) as used in normal daily practice by Indian women.
- Trial name
- NCT01490190
- Testing
- Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Contraception
Birth Control Patch Study
400 healthy women needed contraception will be asked to participate in this study. Half will be given EVRA, half will be given FC Patch low.
- Trial name
- NCT00984789
- Testing
- Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016), Norelgestromin/Ethinylestradiol (EVRA)
- Where
- 23 sites in Austria, Czechia and 1 more
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
The trial is a single-center randomized, double-blind, double-dummy, placebo and positive controlled, parallel group clinical trial.
- Trial name
- NCT00779532
- Testing
- Moxifloxacin, NOMAC-E2 (Org 10486-0 + Org 2317)
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Contraception
IUB(TM) SCu300B - Post Marketing Performance Study in Austria
Participating investigators will locate all IUB B insertions conducted at their facility at least 12 month prior the initiation of study data collection. The study is composed of 2 parts.
- Trial name
- NCT02778061
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ocon Medical Ltd.
Contraception, Change in Bone Mineral Density
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113.
- Trial name
- NCT05461573
- Testing
- Drospirenone
- Where
- 47 sites in United States, Canada
- Volunteers
- 1,542 people, healthy volunteers welcome
- Sponsor
- Insud Pharma